[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633361":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":11,"centralContacts":11,"locations":26,"responsibleParty":45,"collaborators":11,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":11,"eligibilityCriteria":54,"healthyVolunteers":51,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":11,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":11,"overallStatus":29,"whyStopped":11,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Minia University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Temporary Uterine Tourniquet Application","ACTIVE_COMPARATOR",null,[13],"Procedure: Temporary Uterine Tourniquet Application",{"label":15,"type":10,"description":11,"interventionNames":16},"Local Myometrial Epinephrine Injection",[17],"Procedure: Local Myometrial Epinephrine Injection",[19,23],{"type":20,"name":9,"description":21,"armGroupLabels":22,"otherNames":11},"PROCEDURE","The tourniquet will be tightened just enough to achieve visible blanching of the uterus, indicating adequate vascular occlusion, but without excessive tension to avoid tissue damage",[9],{"type":20,"name":15,"description":24,"armGroupLabels":25,"otherNames":11},"Approximately 5-10 mL of the diluted epinephrine will be injected into the myometrium surrounding each fibroid, specifically at the base of the myoma and along the planned incision line, using a laparoscopic injection needle.",[15],[27],{"facility":28,"status":29,"city":30,"state":11,"zip":11,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Minia advanced laparoscopy unit","RECRUITING","Minya","Egypt","EG",{"type":34,"coordinates":35},"Point",[36,37],30.75813,28.09193,{"lat":37,"lon":36},[40],{"name":41,"role":42,"phone":43,"phoneExt":11,"email":44},"Mohamed abdelghfar, Lecturer","CONTACT","+20 10 61624335","mohamedeleboany@gmail.com",{"type":46,"investigatorFullName":47,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Mohamed Hassan Mohamed Abdel Ghfar","Lecturer of Obstetrics and Gynecology","100633361","temporary-uterine-tourniquet-application-versus-local-myometrial-epinephrine-injection-during-laparoscopic-myomectomy-100633361",false,"NCT07525687","Temporary Uterine Tourniquet Application Versus Local Myometrial Epinephrine Injection During Laparoscopic Myomectomy","Inclusion Criteria:\n\n* Female patients aged 18-45 years.\n* Diagnosed with symptomatic uterine leiomyomas requiring laparoscopic myomectomy.\n* Presence of at least one myoma with a diameter ≥3 cm and ≤10 cm.\n* Patients with up to 3 myomas (to standardize surgical complexity).\n* Preoperative hemoglobin level ≥10 g\u002FdL.\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Patients with more than 3 myomas or any myoma larger than 10 cm.\n* Patients with suspected uterine malignancy (e.g., leiomyosarcoma).\n* Patients with known bleeding disorders or on anticoagulant therapy that cannot be safely discontinued.\n* Patients with significant cardiovascular disease, uncontrolled hypertension, or arrhythmias (relative contraindications for epinephrine).\n* Patients with active pelvic infection.\n* Patients with previous extensive uterine surgery (e.g., multiple prior myomectomies or extensive uterine reconstruction) that may compromise uterine integrity.\n* Patients undergoing concurrent major gynecological procedures that might significantly affect blood loss (e.g., hysterectomy, extensive adhesiolysis).\n* Patients with known allergy to epinephrine.\n* Patients unwilling or unable to comply with follow-up protocols.","FEMALE","18 Years","45 Years",{"count":59,"type":60},74,"ESTIMATED","INTERVENTIONAL",[63],"NA","While both local vasoconstrictors and tourniquet application are recognized methods for blood loss control, there is a paucity of head-to-head randomized controlled trials directly comparing these two distinct approaches in laparoscopic myomectomy. Existing data often compare these methods to no intervention or to other less common techniques. A direct comparison is essential to determine which method offers superior hemostasis with an acceptable safety profile in the laparoscopic setting. This study aims to address this gap in the literature.",[66],"Laparoscopic Myomectomy","2026-07-19",{"date":69,"type":70},"2026-07-21","ACTUAL",{"date":72,"type":70},"2026-04-20",{"date":74,"type":60},"2027-01-20",{"name":5,"class":6},1]